中华临床医师杂志（电子版）
中華臨床醫師雜誌（電子版）
중화림상의사잡지（전자판）
CHINESE JOURNAL OF CLINICIANS(ELECTRONIC VERSION)
2013年
14期
6358-6361
,共4页
树突细胞%杀伤细胞%肺肿瘤%P糖蛋白%多药耐药相关蛋白质类
樹突細胞%殺傷細胞%肺腫瘤%P糖蛋白%多藥耐藥相關蛋白質類
수돌세포%살상세포%폐종류%P당단백%다약내약상관단백질류
Dendritic cells%Killer cells%Lung neoplasms%P-glycoprotein%Multidrug resistance-associated proteins
目的：探讨树突状细胞/细胞因子诱导的杀伤细胞（DC/CIK）是否具有人体内逆转肺癌多药耐药（MDR）的作用。方法30例晚期非小细胞肺癌患者接受2个疗程DC/CIK细胞输注。输注前和完成2个疗程细胞输注后，流式细胞术测定 P-糖蛋白（P-gp）和多药耐药相关蛋白（MRP）阳性细胞百分率以及平均荧光强度。结果30例晚期非小细胞肺癌患者全部检测出P-gp和MRP阳性细胞。DC/CIK细胞输注前， P-gp 阳性细胞百分率为（38.67±8.76）%，平均荧光强度2.18±0.34；MRP 阳性细胞百分率为（1.14±0.49）%，平均荧光强度为2.14±0.437。DC/CIK细胞输注后，P-gp阳性细胞百分率为（34.96±6.9）%，平均荧光强度2.07±0.42；MRP阳性细胞百分率为（1.0±0.53）%，平均荧光强度为2.05±0.42。2个周期DC/CIK细胞输注前后，P-gp阳性细胞百分率的差异有统计学意义（t＝5.02，P＜0.001），平均荧光强度的差异有统计学意义（t＝2.18，P＜0.05）；MRP阳性细胞百分率的差异有统计学意义（t＝2.35，P＜0.05），其平均荧光强度的差异有统计学意义（t＝2.16，P＜0.05）。结论 DC/CIK细胞可以在人体内逆转肺癌MDR。
目的：探討樹突狀細胞/細胞因子誘導的殺傷細胞（DC/CIK）是否具有人體內逆轉肺癌多藥耐藥（MDR）的作用。方法30例晚期非小細胞肺癌患者接受2箇療程DC/CIK細胞輸註。輸註前和完成2箇療程細胞輸註後，流式細胞術測定 P-糖蛋白（P-gp）和多藥耐藥相關蛋白（MRP）暘性細胞百分率以及平均熒光彊度。結果30例晚期非小細胞肺癌患者全部檢測齣P-gp和MRP暘性細胞。DC/CIK細胞輸註前， P-gp 暘性細胞百分率為（38.67±8.76）%，平均熒光彊度2.18±0.34；MRP 暘性細胞百分率為（1.14±0.49）%，平均熒光彊度為2.14±0.437。DC/CIK細胞輸註後，P-gp暘性細胞百分率為（34.96±6.9）%，平均熒光彊度2.07±0.42；MRP暘性細胞百分率為（1.0±0.53）%，平均熒光彊度為2.05±0.42。2箇週期DC/CIK細胞輸註前後，P-gp暘性細胞百分率的差異有統計學意義（t＝5.02，P＜0.001），平均熒光彊度的差異有統計學意義（t＝2.18，P＜0.05）；MRP暘性細胞百分率的差異有統計學意義（t＝2.35，P＜0.05），其平均熒光彊度的差異有統計學意義（t＝2.16，P＜0.05）。結論 DC/CIK細胞可以在人體內逆轉肺癌MDR。
목적：탐토수돌상세포/세포인자유도적살상세포（DC/CIK）시부구유인체내역전폐암다약내약（MDR）적작용。방법30례만기비소세포폐암환자접수2개료정DC/CIK세포수주。수주전화완성2개료정세포수주후，류식세포술측정 P-당단백（P-gp）화다약내약상관단백（MRP）양성세포백분솔이급평균형광강도。결과30례만기비소세포폐암환자전부검측출P-gp화MRP양성세포。DC/CIK세포수주전， P-gp 양성세포백분솔위（38.67±8.76）%，평균형광강도2.18±0.34；MRP 양성세포백분솔위（1.14±0.49）%，평균형광강도위2.14±0.437。DC/CIK세포수주후，P-gp양성세포백분솔위（34.96±6.9）%，평균형광강도2.07±0.42；MRP양성세포백분솔위（1.0±0.53）%，평균형광강도위2.05±0.42。2개주기DC/CIK세포수주전후，P-gp양성세포백분솔적차이유통계학의의（t＝5.02，P＜0.001），평균형광강도적차이유통계학의의（t＝2.18，P＜0.05）；MRP양성세포백분솔적차이유통계학의의（t＝2.35，P＜0.05），기평균형광강도적차이유통계학의의（t＝2.16，P＜0.05）。결론 DC/CIK세포가이재인체내역전폐암MDR。
Objective To investigate whether DC/CIK(Dendritic cells/Cytokine induced killer cells) cell can reversal of multidrug resistance (MDR) on lung cancer in the body. Methods 30 cases of patients with advanced non-small cell lung cancer received 2 cycles of DC/CIK cell infusion. Before and after 2 cycles of DC/CIK cells infusion, the percentage of P-gp-positive cells and MRP-positive cells were determined by flow cytometry. Mean fluorescence intensity was determined by flow cytometry. Results 30 cases of patients with advanced non-small cell lung cancer were all detected P-gp-positive cells and MRP-positive cells. Before DC/CIK cells infusion, the percentage of P-gp-positive cells was 38.67±8.76, the fluorescence intensity of P-gp was 2.18 ±0.34; the percentage of MRP- positive cell was 1.14±0.49, the fluorescence intensity of MRP was 2.14±0.437. After DC/CIK cells infusion, the percentage of P-gp-positive cells was 34.96±6.9, the fluorescence intensity of P-gp was 2.07±0.42;the percentage of MRP-positive cell was 1.0±0.53, the fluorescence intensity of MRP was 2.05±0.42. The difference of the percentage of P-gp-positive cells was statistically significant(P<0.001) before and after 2 cycles of DC/CIK cells infusion. The fluorescence intensity of P-gp also had significant difference(P<0.05).The difference of the percentage of MRP-positive cells was statistically significant(P<0.05) before and after 2 cycles of DC/CIK cells infusion. The fluorescence intensity of MRP had significant difference(P<0.05). Conclusion DC/CIK cells can reverse the multidrug resistance on lung cancer in the body.
